Evommune, Inc. (EVMN) stock
EVMNNYSEPharmaceutical PreparationsFiscal year ends December 31
$8.02−0.60 (-6.96%)
Close on Nov 12, 2026Market cap $291.06MP/E –Yield –
Evommune cash
Cash and short-term investments held at the end of each period.
Evommune's cash was $168.64M at Sep 30, 2026. For fiscal 2025 it was $149.20M, up 106.5% from the year before.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $149.20M | +106.5% |
| FY2024 | Dec 31, 2024 | $72.25M | +147.2% |
| FY2023 | Dec 31, 2023 | $29.23M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $168.64M | +121.7% |
| Q2 FY2026 | Jun 30, 2026 | $200.79M | +224.7% |
| Q1 FY2026 | Mar 31, 2026 | $211.46M | +3607.3% |
| Q4 FY2025 | Dec 31, 2025 | $149.20M | +106.5% |
| Q3 FY2025 | Sep 30, 2025 | $76.06M | +319.2% |
| Q2 FY2025 | Jun 30, 2025 | $61.84M | +111.5% |
| Q1 FY2025 | Mar 31, 2025 | $5.70M | – |
| Q4 FY2024 | Dec 31, 2024 | $72.25M | – |
| Q3 FY2024 | Sep 30, 2024 | $18.15M | – |
| Q4 FY2023 | Dec 31, 2023 | $29.23M | – |
See a number that looks wrong?